Is It Safe to Take Glipizide and Fluconazole Together?

Glipizide and fluconazole can be taken together, but the combination requires careful monitoring because fluconazole significantly increases glipizide levels in the bloodstream, raising the risk of dangerously low blood sugar. According to FDA labeling data, fluconazole increases glipizide exposure by an average of 56.9%, which can intensify the drug's blood-glucose-lowering effects and potentially cause severe hypoglycemia.

What the FDA Says

The FDA classifies the interaction between glipizide and fluconazole as major severity. Fluconazole, an azole antifungal drug used to treat yeast infections and other fungal infections, directly inhibits the liver enzymes responsible for breaking down glipizide. This pharmacokinetic interaction means that when both drugs are used simultaneously, glipizide accumulates in the body to higher-than-normal concentrations.

The FDA label for glipizide warns that certain medications—including azole antifungals like fluconazole—may potentiate the hypoglycemic effect, and close monitoring of blood glucose is recommended when these drugs are combined. The clinical significance of this interaction is substantial: a mean increase in glipizide area-under-the-curve (AUC) of 56.9% translates to meaningfully higher drug exposure in most patients, with some individuals experiencing increases as high as 81%.

How This Interaction Works

Understanding the mechanism behind this interaction requires a brief look at how glipizide is metabolized. Glipizide is a second-generation sulfonylurea—a class of oral medications that lower blood sugar by stimulating insulin release from pancreatic beta cells. After you take glipizide orally, it is absorbed through the gastrointestinal tract and then processed by the liver through oxidative metabolism, primarily via the cytochrome P450 enzyme system, specifically CYP2C9 and CYP3A4.

Fluconazole is a potent inhibitor of both CYP2C9 and CYP3A4. When fluconazole enters the bloodstream, it binds competitively to these liver enzymes, blocking them from metabolizing glipizide. Think of the liver enzymes as a bottleneck: normally, glipizide moves through relatively quickly, but when fluconazole is present, it clogs the pathway. The result is that glipizide remains in the body longer and builds to higher concentrations, causing prolonged and intensified blood-glucose-lowering effects.

This is not an absorption interaction (both drugs are absorbed normally) and not a protein-binding displacement issue. It is a pure hepatic metabolism inhibition—fluconazole slows the enzymatic clearance of glipizide from the body. The clinical consequence is an increased risk of hypoglycemia, particularly in the hours after a glipizide dose or in patients who have not eaten enough carbohydrate.

Who Is Most at Risk

Not all patients taking glipizide and fluconazole together face the same level of risk. Several factors influence susceptibility to dangerous hypoglycemia:

• Renal function: Patients with impaired kidney function cannot clear drugs as efficiently, so they accumulate glipizide more readily.
• Hepatic function: Pre-existing liver disease amplifies the metabolism-inhibition effect of fluconazole.
• Age: Older adults (over 65) generally have reduced hepatic metabolism and are at higher hypoglycemia risk overall.
• Glipizide dose: Patients on higher glipizide doses (e.g., 10–20 mg daily) face a steeper risk increase than those on lower doses (5 mg daily).
• Nutritional status: Patients who skip meals or have irregular eating patterns are more vulnerable to severe hypoglycemic episodes when glipizide levels rise unexpectedly.
• Concurrent medications: Other drugs that lower blood sugar (insulin, metformin, GLP-1 agonists) amplify the hypoglycemic risk.
• Duration of fluconazole therapy: Short-course fluconazole (e.g., a single 150 mg dose for vaginal candidiasis) poses less risk than multi-day courses (e.g., 400 mg daily for systemic fungal infection).

Clinical Scenario 1: Vaginal Candidiasis in a Diabetic Woman

Maria is a 58-year-old woman with type 2 diabetes managed on glipizide 10 mg twice daily. Her diabetes is reasonably controlled, with a recent HbA1c of 7.2%. She develops a yeast infection and visits her primary care physician, who prescribes fluconazole 150 mg orally as a single dose. Maria takes the fluconazole on a Friday afternoon.

Maria is not aware that fluconazole interacts with her glipizide. She takes her usual glipizide dose (10 mg) on Saturday morning with breakfast, eats a normal meal, and feels fine. But by mid-afternoon, after a 2-hour walk with friends and without a snack, she begins to feel dizzy and confused. Her hands shake slightly. She recognizes these as hypoglycemia symptoms, checks her blood sugar at a nearby pharmacy, and discovers it is 52 mg/dL—dangerously low. A pharmacy staff member gives her glucose tablets, which resolve the symptoms within minutes.

What happened? Although Maria took only a single 150 mg dose of fluconazole, it was still sufficient to inhibit her liver enzymes meaningfully. Her glipizide levels rose, her beta cells released more insulin than usual, and combined with the physical activity (which also lowers blood sugar), she developed symptomatic hypoglycemia. Fortunately, she recognized the warning signs and treated it quickly. But if she had been driving or alone, the outcome could have been serious.

Clinical Scenario 2: Systemic Fungal Infection on Multiple Medications

James is a 72-year-old man with type 2 diabetes, chronic kidney disease stage 3, and hypertension. His diabetes is managed with glipizide 5 mg twice daily and metformin 500 mg twice daily (his kidney function precludes higher metformin doses). He also takes lisinopril for blood pressure. He is hospitalized with a urinary tract infection complicated by candiduria (yeast in the urine), and his infectious disease physician prescribes fluconazole 400 mg daily intravenously for 5 days.

On day 2 of fluconazole therapy, James's blood glucose readings begin to trend downward. On day 3, before lunch, his glucose is 68 mg/dL (normal fasting is 70–100 mg/dL). On day 4, he has a particularly low reading of 58 mg/dL in the afternoon, and a nursing staff member notes he is unusually drowsy and difficult to arouse. His blood glucose is confirmed at 54 mg/dL. He receives intravenous dextrose and recovers alert and oriented within 15 minutes.

The hospital pharmacist reviews the medication interaction: James is on a prolonged, high-dose fluconazole course for a serious infection. His glipizide exposure has likely increased 50–80% due to CYP inhibition, and his reduced renal function (eGFR ~40 mL/min) means he cannot clear drugs as efficiently. Additionally, his concurrent metformin enhances the insulin-secreting effect of glipizide. The combination created a perfect storm for severe hypoglycemia. The clinical team decides to reduce his glipizide dose to 2.5 mg twice daily and schedule glucose checks every 4 hours. Over the remaining 2 days of fluconazole therapy, his glucose stays in the safe range (100–160 mg/dL).

What to Do: Management Guidance

For Patients:

• Inform your doctor and pharmacist: When prescribed fluconazole for any infection, explicitly mention all your diabetes medications, including glipizide. Do not assume your doctors have cross-checked every medication.
• Monitor blood glucose more frequently: If your doctor approves combined use, check your blood sugar before meals, 2 hours after meals, and at bedtime—not just the once-daily or twice-daily routine you may normally follow.
• Recognize hypoglycemia warning signs: Shakiness, sweating, anxiety, rapid heartbeat, hunger, tingling lips, confusion, or unusual fatigue can all signal low blood sugar. Treat immediately with 15 grams of fast-acting carbohydrate (glucose tablets, 4 oz fruit juice, 1 tablespoon honey).
• Eat regular meals: Do not skip meals while on both drugs, and avoid prolonged fasting or intense exercise without eating extra carbohydrate first.
• Keep a record: Write down your blood glucose readings and any symptoms. Share this with your doctor after the fluconazole course ends.

For Healthcare Providers:

• Assess necessity: If possible, choose a non-interacting antifungal alternative. For vaginal candidiasis, a single 150 mg fluconazole dose is often adequate and poses minimal risk. For systemic fungal infections, consider agents that do not inhibit CYP2C9/3A4 (e.g., caspofungin, if clinically appropriate).
• Reduce glipizide dose: If fluconazole is essential and glipizide cannot be replaced, reduce the glipizide dose by 25–50% during fluconazole co-administration. Monitor glucose closely and adjust further based on readings.
• Arrange intensive monitoring: For hospitalized patients on prolonged fluconazole, order glucose checks every 4–6 hours, not daily. In outpatients, ask the patient to check glucose before meals and at bedtime for the duration of fluconazole therapy and 2–3 days afterward (clearance time).
• Consider alternative sulfonylureas: If switching glipizide to a non-sulfonylurea agent (e.g., metformin, a GLP-1 agonist, or SGLT2 inhibitor) is feasible, it eliminates the interaction entirely.
• Document the interaction: Record in the patient chart that the interaction was identified and how it was managed, so future providers are aware.

When to Call Your Doctor or Pharmacist

Seek immediate medical attention if you experience any of the following while taking glipizide and fluconazole:

• Severe shakiness, profuse sweating, or palpitations
• Confusion, slurred speech, or difficulty concentrating
• Loss of consciousness or seizure
• Persistent blood glucose readings below 70 mg/dL, even after eating carbohydrate
• Unusual fatigue or weakness lasting more than a few minutes after a meal
• Chest pain or shortness of breath (rare but can occur with severe hypoglycemia)

Contact your pharmacist or doctor (non-emergent) to report:

• Any blood glucose reading below 90 mg/dL, especially if it happens more than once
• New or worsening symptoms of yeast infection (not improving on fluconazole)
• Questions about whether your dose of glipizide should be adjusted
• Concern about how long you should continue monitoring glucose after fluconazole ends

Key Takeaways

• Fluconazole increases glipizide blood levels by an average of 57%, raising hypoglycemia risk significantly. The interaction is classified as major severity by the FDA.
• The mechanism is hepatic enzyme inhibition: Fluconazole blocks the CYP2C9 and CYP3A4 enzymes that normally clear glipizide from the body, causing it to accumulate.
• Older adults, patients with kidney or liver disease, and those on higher glipizide doses face the highest risk. A single 150 mg fluconazole dose for vaginal yeast infection poses less risk than multi-day courses for systemic fungal infection.
• Management includes reducing glipizide dose by 25–50%, increasing glucose monitoring frequency, and ensuring regular meal timing. When possible, non-interacting antifungal alternatives should be used instead.
• Patients and providers must communicate openly about all medications. Early identification of this interaction prevents severe hypoglycemic episodes that can cause seizures, loss of consciousness, or accidents.

Related Drug Interactions

If you are taking glipizide or fluconazole, you may want to review other significant interactions:

• Glipizide and metformin interaction — both lower blood sugar and can cause combined hypoglycemic effect
• Fluconazole and warfarin interaction — fluconazole increases warfarin levels and bleeding risk
• Glipizide and clarithromycin interaction — another macrolide antibiotic that can increase glipizide levels

Sources

• FDA Drug Labeling via OpenFDA: Glipizide https://open.fda.gov
• FDA Drug Labeling via OpenFDA: Fluconazole https://open.fda.gov
• NIH National Library of Medicine, PubMed Central: CYP450 Enzyme Inhibition by Azole Antifungals (https://pubmed.ncbi.nlm.nih.gov)
• American Diabetes Association Standards of Medical Care in Diabetes: Pharmacologic Management of Type 2 Diabetes (https://diabetes.org)
• Micromedex: Glipizide-Fluconazole Interaction Documentation
• UpToDate: Sulfonylurea Hypoglycemic Agents and Drug Interactions

Before combining any new medication with glipizide or fluconazole, check your complete medication list at checkdruginteractions.com. Our comprehensive drug interaction checker, powered by over 250,000 FDA drug labels, will identify all known interactions across your medications and help you have an informed conversation with your pharmacist or physician. Early detection of drug interactions prevents serious adverse events and keeps you safe.